ABSTRACT
Recently, high-resolution, noninvasive, multimodality in vivo molecular imaging with PET, SPECT, CT, and MRI, employing fusion algorithms has revolutionized EBPT of NDDs, CVDs, and MDR malignancies. However, specific RPs for the accurate diagnosis and effective clinical treatment of AD, PD, drug addiction, and other cognitive impairments remains a significant challenge. Currently, multimodality fusion neuroimaging is utilized for the determination of PKs and pre-clinical development of RPs, in vivo monitoring of stem cell transplantation therapy, nicotinic acetylcholine receptors (nAChRs) investigations, regional cerebral blood flow, and glucose utilization studies in cognitively-impaired subjects employing noninvasive microPET and nano-SPECT imaging. Furthermore, multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT.
